The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus

T Volz, L Allweiss, MB ḾBarek, M Warlich… - Journal of …, 2013 - Elsevier
BACKGROUND & AIMS: Currently approved antivirals rarely cure hepatitis B virus (HBV)
infection. Therefore additional therapeutic strategies interfering with other viral replication
steps are needed. Using synthetic lipopeptides derived from the HBV envelope protein, we
previously demonstrated prevention of de novo HBV infection in vivo. We aimed at
investigating the ability of the lipopeptide Myrcludex-B to block HBV spreading post-
infection. METHODS: uPA/SCID mice reconstituted with human hepatocytes were infected …